🟢 Amneal Pharmaceuticals is trading 5.77% up today after FDA approval and immediate generic lanreotide launch

Amneal Pharmaceuticals is trading 5.77% up at $19.79 after FDA approval and immediate U.S. launch of generic lanreotide injection.

• FDA approval came September 18, 2026; the launch targets acromegaly and certain neuroendocrine tumors.
• The product references Somatuline Depot, received Competitive Generic Therapy designation, and addresses approximately $983 million in annual branded sales.
• Broader risk-on sentiment, including gains in major indexes, may also be supporting the move.